Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Our AI ranks Exelixis, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Exelixis, Inc. is a large-cap company with a market capitalization of $15.42B. It ranks number 8 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For EXEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -4.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, EXEL included.
Follow EXEL free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
| Metric | EXEL | Rank |
|---|---|---|
| Market Cap | $15.42B | 8/60 |
| P/E Ratio | 17.93x | 12/15 |
| P/B Ratio | 8.36x | 15/49 |
| EPS | $3.47 | – |
| Book Value/Share | $7.44 | – |
| Revenue/Share | $9.22 | – |
| FCF/Share | $3.91 | – |
| Metric | EXEL | Rank |
|---|---|---|
| ROE | 52.9% | 3/47 |
| ROA | 39.1% | 1/50 |
| ROIC | 52.0% | 3/53 |
| Gross Margin | 95.5% | 5/24 |
| Operating Margin | 38.0% | 5/40 |
| Net Margin | 33.5% | 2/37 |
| EBT Margin | 38.0% | 5/42 |
| Tax Rate | 19.6% | – |
| Metric | EXEL | Rank |
|---|---|---|
| Current Ratio | 3.46x | 43/59 |
| Quick Ratio | 3.38x | 13/28 |
| D/E Ratio | 0.35x | 31/53 |
| Financial Leverage | 1.35x | 30/52 |
| Interest Coverage | 6.4x | 10/37 |
| Working Capital | $889M | 15/59 |
| Metric | EXEL | Rank |
|---|---|---|
| Operating Cash Flow | $1.17B | 5/57 |
| Free Cash Flow | $968M | 5/50 |
| Capital Spending | -$206M | 47/50 |
| OCF Growth YoY | 72.5% | 3/16 |
| FCF Growth YoY | 248.8% | 2/15 |
| FCF/Sales | 42.4% | 5/32 |
| CapEx/Sales | 9.0% | 8/32 |
| Metric | EXEL | Rank |
|---|---|---|
| Asset Turnover | 0.92x | 7/36 |
| Receivables Turnover | 7.1x | 8/24 |
| Inventory Turnover | 3.6x | 8/23 |
| Fixed Assets Turnover | 24.6x | 8/37 |
| Days Sales Outstanding | 51 days | 17/24 |
| Days Inventory | 103 days | 16/23 |
| Payables Period | 139 days | 7/26 |
| Cash Conversion Cycle | 15 days | 13/18 |
| Metric | EXEL | Rank |
|---|---|---|
| Total Revenue | $2.28B | 6/37 |
| Operating Income | $1.11B | 4/54 |
| Net Income | $976M | 5/50 |
| R&D Expense | $1.02B | 10/56 |
| SG&A Expense | $642M | 7/22 |
| Cost of Goods Sold | $102M | 16/26 |
| Metric | EXEL | Rank |
|---|---|---|
| Shares Outstanding | 248M | – |
| Net Income Growth | 119.0% | 3/12 |
| EPS Growth | 395.7% | 1/14 |
| Total Current Assets | $1.25B | 50.1% of assets |
| Cash & Short-term Investments | $281M | 11.3% of assets |
| Accounts Receivable | $322M | 12.9% of assets |
| Inventory | $29M | 1.2% of assets |
| Total Liabilities | $650M | 26.1% of assets |
| Short-term Debt | $323M | 12.9% of assets |
Companies classified under the same SEC industry code as Exelixis, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| EXEL Exelixis, Inc. | ▼ | $15.42B |
| AMGN Amgen Inc | ▼ | $233.82B |
| GILD Gilead Sciences, Inc. | ▶ | $193.67B |
| MRNA Moderna, Inc. | ▲ | $87.04B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $38.14B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| BNTX Biontech Se | ▲ | $22.18B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.79B |
| TECH Bio-Techne Corp | ▼ | $11.38B |
| QGEN Qiagen N.V. | ▶ | $10.01B |
| RGEN Repligen Corp | ▲ | $9.90B |
| IBRX Immunitybio, Inc. | ▲ | $9.73B |
| PCVX Vaxcyte, Inc. | ▲ | $9.47B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.37B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.71B |
| TWST Twist Bioscience Corp | ▲ | $8.32B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.17B |
| IMVT Immunovant, Inc. | ▲ | $5.52B |
| KOD Kodiak Sciences Inc. | ▲ | $5.39B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.86B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.57B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $2.99B |
| DNLI Denali Therapeutics Inc. | ▶ | $2.81B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| LIFE Atyr Pharma Inc | ▲ | $2.37B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.07B |
| VCEL Vericel Corp | ▶ | $2.05B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| NVAX Novavax Inc | ▲ | $1.86B |
| ALVO Alvotech | ▲ | $1.78B |
| MESO Mesoblast Ltd | ▶ | $1.70B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.69B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▼ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.18B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.02B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $902M |
| MGTX Meiragtx Holdings Plc | ▶ | $891M |
| SLBT Sl Science Holding Ltd | ▶ | $873M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $825M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| SANA Sana Biotechnology, Inc. | ▲ | $680M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| PRME Prime Medicine, Inc. | ▲ | $629M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $593M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
| VALN Valneva Se | ▼ | $521M |
(Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis ...
Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2025 Financial Results Conference Call. My name is [ Towanda ], and I'll be your operator for today. As a ...
Exelixis Inc stock has reached an all-time high, hitting a price of $61.23. The biotech company now commands a market ...
Our AI ranks Exelixis, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For EXEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -4.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Exelixis, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
60 issuers in our coverage, EXEL included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.